NYSEARCA:TOVX - NYSE Arca - US87164U5083 - Common Stock - Currency: USD
- VCN-01 alcanza los criterios de valoración primarios de eficacia y seguridad para el adenocarcinoma pancreático ductal en el ensayo clínico de Fase 2b...
- VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial - - Closed a public...
ROCKVILLE, Maryland, May 09, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), («Theriva» o la «empresa»), una empresa diversificada en...
Theriva stock is trading higher after the company announced it was selected as a finalist for Merck's KGaA's EMEA Advance Biotech Grant.
ROCKVILLE, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage...
ROCKVILLE, Maryland, May 08, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), una empresa diversificada de fase clínica que desarrolla...
The offering comes on the heels of encouraging data from the Virage Phase 2b trial, which demonstrated significant improvements in overall survival and duration of response for patients receiving Theriva's lead product candidate, VCN-01.
Mentions: KTTA
- Los pacientes tratados con VCN-01 (zabilugene almadenorepvec) más quimioterapia estándar con gemcitabina/nab-paclitaxel presentaron un aumento de la...
ROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage...
En el Congreso de la European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global), se presentarán datos provisionales ciegos de...
Interim blinded safety and pharmacokinetic data to be presented at the Congress of the European Society of Clinical Microbiology and Infectious Diseases...
El Comité independiente para la monitorización de los datos (IDMC) consideró que el VCN-01 lo toleraban bien los pacientes con adenocarcinoma pancreático...
ROCKVILLE, Maryland, March 19, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), una empresa diversificada de fase clínica que...
ROCKVILLE, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics...
– Una vez finalizada la inscripción a VIRAGE, el ensayo clínico de Fase 2b de VCN-01 para el adenocarcinoma pancreático ductal (PDAC) metastásico, los...
– Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected in Q2 2025...
ROCKVILLE, Maryland, March 06, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), una empresa diversificada de fase clínica que...
ROCKVILLE, Md., March 05, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics...
ROCKVILLE, Maryland, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), una empresa diversificada de fase clínica que desarrolla...
ROCKVILLE, Md., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics...
Logro del objetivo de inscripción de 92 pacientes evaluables en VIRAGE, el ensayo clínico de Fase 2b de VCN-01 en pacientes con adenocarcinoma pancreático...
Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic pancreatic ductal...
El ganador se presentará en BIO-Europe 2024 que se celebrará en Estocolmo (Suecia)...